Alzheimer’s Association International Conference
12 July 202615 July 2026
London, UK
AAIC is the Alzheimer’s Association’s flagship global meeting and one of the most influential conferences dedicated to Alzheimer’s disease and broader dementia science. The programme spans the full research-to-care continuum, including basic and translational research, biomarkers, clinical manifestations, drug development, public health, and dementia care.
It is a major platform for sharing new findings, discussing best practices, and connecting across disciplines to accelerate progress in prevention, diagnosis, treatment and care.
Who the audience is and how many attend
Audience
- Dementia researchers and neuroscientists across academia and industry
- Clinicians and clinical investigators involved in diagnosis and treatment of Alzheimer’s and related disorders
- Drug developers, clinical trial teams and medical affairs professionals
- Public health experts and policy stakeholders focused on dementia prevention and care systems
- Care and dementia-professional communities, including interdisciplinary health professionals
Scale
- Posters: 4,000
- Podium presentations: 800
What to expect
- A major abstract-driven programme with high volumes of posters and podium presentations
- Cutting-edge updates across biomarkers, therapeutics development, clinical research and care models
- Strong networking density across global research and clinical communities, plus industry participation
- Hybrid access for broader participation beyond the host city
Today's issue
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze